Healthcare Sector Announce Awards, Conference Participation, Partnerships, and Closure of Public Offering - Research Report on Regeneron, Alnylam, Galena Biopharma, Amedisys, and Aeterna Zentaris

NEW YORK, December 3, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Galena Biopharma, Inc. (NASDAQ: GALE), Amedisys Inc. (NASDAQ: AMED), and Aeterna Zentaris Inc. (USA) (NASDAQ: AEZS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Regeneron Pharmaceuticals, Inc. Research Report

On November 25, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) and Sanofi jointly announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. According to the Company, Dupilumab is a fully-human monoclonal antibody, developed by Regeneron in association with Sanofi for the treatment of asthma, atopic dermatitis, and nasal polyposis. George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, said, "We appreciate the recognition by Scrip that dupilumab is one of the most exciting emerging clinical candidates in the industry. We feel that this award is additional validation of the overall depth and productivity of our R&D team and the powerful VelociSuite® technologies they employ, which have delivered dupilumab and several other investigational therapeutic opportunities." The Full Research Report on Regeneron Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8ea7_REGN

--

Alnylam Pharmaceuticals, Inc. Research Report

ON November 25, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that its management will present a Company overview at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 11:00 a.m. ET at The New York Palace in New York City. Alnylam stated that it will also make a presentation at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 7:50 a.m. ET at the Four Seasons Hotel in Boston. According to the Company, a live audio webcast of both the presentations will be available on the News & Investors section of Alnylam's website. The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5b29_ALNY

--

Galena Biopharma, Inc. Research Report

On November 26, 2013, Galena Biopharma, Inc. (Galena Biopharma) announced that its President and CEO, Mark J. Ahn, Ph.D., will present a corporate update at the 25th Annual Piper Jaffray Healthcare Conference. According to the Company, the presentation will take place on Tuesday, December 3, 2013 at 8:10 a.m. ET at The New York Palace Hotel in New York, NY. The Company stated that interested parties can access an webcast of the presentation at the Investors section of Galena Biopharma's website. The Full Research Report on Galena Biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cad6_GALE

--

Amedisys Inc. Research Report

On November 22, 2013, Amedisys Inc. (Amedisys) announced that it has teamed up with Antidote Education Company to offer Continuing Education webinars for physicians on two increasingly important topics - home health and hospice care. The Company stated that it's specially designed webinar, "It's Not Easy, But It's Not That Hard: Discussing Hospice Goals of Care," will deliver insights into the services available through hospice care as well as advice on carrying on the crucial, end-of-life conversation with patients and their families. Additionally, Amedisys informed that its webinar to educate physicians about the clinical advantages of home health care, "Health Care at Home" will address eligibility requirements and feature advice about how home health care can improve patient outcomes, prevent unnecessary hospital readmissions and lower healthcare spending. The Full Research Report on Amedisys Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/56b5_AMED

--

Aeterna Zentaris Inc. (USA) Research Report

On November 25, 2013, Aeterna Zentaris Inc. (USA) (Aeterna Zentaris) announced the closing of its previously announced public offering of 13.1 million units, generating net proceeds of c.$13.7 million, with each unit consisting of one common share and one whole warrant to purchase one common share, at a purchase price of $1.15 per unit. According to the Company, each warrant is exercisable for a period of five years at an exercise price of $1.60 per share. Aeterna Zentaris stated that Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC acted as co-manager for the offering and net proceeds from the same will be used to continue to fund its ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin (AEZS-108) program, secondly for its macimorelin acetate (AEZS-130) program, including the preparation of its commercial launch, as well as for the potential addition of commercialized products to the Company's pipeline, future negative cash flow, general corporate purposes and working capital. The Full Research Report on Aeterna Zentaris Inc. (USA) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3499_AEZS

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner